The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
New studies in JACC highlight improvements in cardiac structure and function among CABG patients, as well as changes in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback